[태그:] 영문
-

3billion Secures 300 Billion KRW in Post-IPO Funding to Accelerate Global AI Genetic Diagnostics Leadership
■ Financial Stability Secured via CPS and CB Mix; Focus on U.S. Insurance Market Entry and Expansion of Diagnostic Portfolio ■ 0% Surface and Maturity Interest Rates: Major Institutional Investors Including Kiwoom PE and GVA Asset Management Participate ■ Targeting 30 Million Rare Disease Patients in the U.S. and Diversifying Portfolio into Non-Symptomatic Screening Markets…
-

3billion Visits Embassy of Argentina in Seoul to Discuss Expanding Precision Medicine Network in South America
SEOUL, South Korea – 3billion announced that it recently conducted an official visit to the Embassy of Argentina in Seoul to discuss strategic cooperation with Ambassador Darío Celaya and key embassy officials. The meeting was held following a formal invitation from Ambassador Darío César Celaya Alvarez, with María Virginia Yapur (Head of the Commercial Section)…
-

3billion Presents GEBRA™ SaaS Implementation and Global Expansion at AWS HealthTech Seminar
3billion Shares GEBRA™ SaaS Implementation and Global Expansion Story at ‘HealthTech Global Expansion Seminar 2026’ On April 28, 3billion participated as a speaker at the ‘HealthTech Global Expansion Seminar 2026’ hosted by Amazon Web Services (AWS), where the company shared its experience in building the SaaS platform for GEBRA—its AI-powered genetic variant interpretation software—and its…
-

Delegation from Puerto Rico’s DEDC Meets with 3billion
On April 22, a high-level delegation from Puerto Rico’s Department of Economic Development and Commerce (DEDC) and Invest Puerto Rico (Invest PR) visited the 3billion. The meeting was organized to explore strategic cooperation for 3billion’s expansion into the United States and Latin American (LATAM) markets, particularly as Puerto Rico is recognized as one of the…
-
![Differences Between Raw Data and Clinical Reports | NGS Data Analysis Workflow [Part 2]](http://d15q5w6b9vqac5.cloudfront.net/wp-content/uploads/2026/05/04180709/7.png)
Differences Between Raw Data and Clinical Reports | NGS Data Analysis Workflow [Part 2]
📍Key Takeaways Missed Part 1? Read it here! [Go to Article] Why do raw data and clinical reports differ? “Why wasn’t this variant reported?” After WES/WGS testing, many users review their VCF files (annotated data).And very naturally, they ask questions like: To answer these questions, we need to clarify one key point first. Raw data…
-

81 Patients Found New Answers Through Reanalysis of Genetic Testing: April 2026
Is a single genetic test result the end of the diagnostic journey? At 3billion, we believe diagnosis is an ongoing process. That’s why we focus not only on the test itself, but on what comes after:Reanalysis. For all cases previously reported as Inconclusive or Negative,3billion performs automated reanalysis through a continuous system.Each month, dozens of…
-
![How is NGS data actually generated? | NGS Data Analysis Workflow [Part 1]](http://d15q5w6b9vqac5.cloudfront.net/wp-content/uploads/2026/04/04180534/5.png)
How is NGS data actually generated? | NGS Data Analysis Workflow [Part 1]
📍Key Takeaways When you order a genomic test and receive a report, you typically see a summary of a few variants along with their interpretations.However, behind those results lies a much more complex analytical process than it may appear. In this article, we will walk through how WES/WGS-based testing is actually performed, focusing on the…
-

KYNU Reconsidered: A Missing Piece in the IDO1 Inhibitor Story?
📍Key Takeaways1. CD8 T cells can’t degrade kynurenine — KYNU is missing. That’s why T cell suppression persists even when IDO1 is blocked. 2. G-APCs express 32× more KYNU than M-APCs. The APC subtype in the tumor microenvironment may determine whether kynurenine-induced suppression happens at all. 3. KYNU-expressing G-APCs restore CD8 T cell function —…
-

Marfan Syndrome: A Summary of Genetic Causes and Ghent Criteria
📍Key Takeaways Marfan syndrome is a systemic connective tissue disorder caused by pathogenic variants in the FBN1 gene. Affecting approximately 1 in 5,000 individuals worldwide, it carries life-altering cardiovascular risks that are largely preventable with timely diagnosis and surveillance. Yet diagnostic delay — averaging 5 to 7 years in published cohorts — remains a persistent…
-

Fragile X Syndrome: The FMR1 Mutation Hidden Behind Autism and Intellectual Disability
📍Key Takeaways Fragile X Syndrome (FXS) is a genetic disorder characterized by intellectual disability and features of autism spectrum disorder. It is the most common single-gene cause of inherited intellectual disability, and it carries an average diagnostic delay of several years from initial clinical concern. 1. FMR1 and CGG Repeat Expansion — How Full Mutation…